Good morning, ladies and gentlemen. I am Dr. Henry Ji, President and CEO of Sorrento Therapeutics, and it is my pleasure to welcome you to our 2021 annual meeting. We are delighted that so many of you are able to join us today for this virtual meeting. As Chairman of this meeting, I hereby call the meeting to order and appoint Brian Song, the Company General Counsel, to serve as the Secretary. I would also like to introduce Andy Kimball of Ernst & Young, our independent registered public accounting firm. During the Q&A period at the end of today's session, Mr. Kimball will be able to answer any appropriate questions you may have concerning the independent audit. The Board of Directors has appointed John Comas of Broadridge Financial Solutions to act as Inspector of Election for the meeting. Mr. Comas has previously taken his oath as Inspector of Election. We will file the executed oath with the records of this meeting. Many stockholders have already submitted their proxies. All proxies will be voted as marked by the stockholders signing them. If you have voted by proxy, you do not need to take any further action. If you wish to vote during this meeting, please log in as a stockholder by entering the 16-digit control number you received with your proxy materials and clicking on the Vote Here button on your screen. The Secretary will now review the agenda, rules of conduct, and procedures for today's meeting, and present the affidavit of mailing of the notice of meeting and the accompanying proxy material of annual report. Thank you, Henry. Upon logging into this meeting, you are presented with an agenda and the rules of conduct and procedures for the annual meeting. To conduct an orderly meeting, we ask that participants abide by these rules. As stated in the rules of conduct, only validated stockholders may ask questions in the designated field on the web portal. Should you desire to ask a question during the meeting, please submit your question in the designated field on the web portal. After the formal meeting has been adjourned, we will attempt to answer as many questions as time allows, but only questions that are relevant to the meeting or the business of the company will be addressed. As stated in the rules of conduct, we ask that you restrict your questions to the agenda items that are before us. We will try to address any appropriate questions that we do not answer on our company website. Thanks to everyone for your cooperation with these rules. Turning ahead to the five items of business on today's agenda, we have the election of the directors, the vote on the ratification of the appointment of the Company's independent registered public accounting firm, the vote on the approval on an advisory basis of the compensation of the Company's named executive officers, the vote on the approval, also on an advisory basis, of the frequency of future advisory votes on the compensation of the Company's named executive officers, and finally, the vote on the approval of the compensation of Dr. Henry Ji as the Executive Chairperson of Scilex Holding Company. Each of these items is described in the proxy statement filed with the SEC on October 5, 2021. After the formal part of our meeting, there will be a Q&A session. The Board of Directors set September 24, 2021, as the date of record for this stockholders' meeting. We have at this meeting a record of stockholders as of that date. A duplicate record has been on file at the principal place of business of the Company for the last 10 days and has been available for inspection by any stockholder during normal business hours during that period. Mr. Chairman, I present the affidavit of mailing signed by Joanne Vogel of Broadridge Financial Solutions, which states that the notice of meeting, accompanying proxy materials, and annual report for this meeting was mailed on October 5, 2021, to stockholders of record as of the close of business on September 24, 2021, the record date for the stockholders entitled the notice of this meeting, which is also in accordance with the bylaws of the Company. Thank you, Brian. I direct that the affidavit of mailing be made part of the minutes of the meeting. Our first order of business at this meeting is to determine whether the shares represented at the meeting are sufficient to constitute a quorum for the purpose of transacting business. Brian, do you have a report? Yes. I have been advised by the Inspector of Election that approximately 65% of the Company's issued and outstanding shares entitled to vote is represented at today's meeting. This is sufficient to constitute a quorum for the purpose of transacting business at this meeting. Thank you, Brian. The report of the Secretary on the existence of a quorum is accepted. Since a majority of Company's shares are represented here today, I declare that a quorum is present and that the meeting is duly constituted. It is 12:05 P.M. Pacific Time. The polls are now open for voting. If you wish to vote now, whether or not you already submitted a proxy, then you may vote using the web portal. We may now proceed to transact the business for which this meeting has been called. The next order of business is a description of matters properly brought before this meeting. The first proposal is for the election of directors. Seven directors shall be elected at today's meeting, each to serve a one-year term until the 2022 annual meeting of stockholders or until his or her respective successor is duly elected and has qualified. As indicated in the Company's proxy statement, the Board of Directors has nominated and recommends a vote for Dr. Henry Ji, Mr. Dorman Followwill, Dr. Kim Janda, Mr. David Lemus, Mr. Jaisim Shah, Dr. Yue Alexander Wu, and Mrs. Elizabeth Czerepak. The Company's bylaws require that a stockholder provide advance notice to the Company of a stockholder's intent to nominate a person as directors. No such notice was received. Accordingly, I declare the nomination for directors closed. We will now move to Proposal 2. The second proposal being submitted to stockholders for action is the ratification of the appointment of Ernst & Young as our independent registered public accounting firm for the fiscal year ending December 31, 2021. We will now move to Proposal 3. The third proposal being submitted to stockholders for action is the approval on an advisory basis of the compensation of our named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission. We will now move to Proposal four. The fourth proposal being submitted to stockholders for action is the vote on an advisory basis of the frequency of future advisory votes on the compensation of the Company's named executive officers. We will now move to Proposal five. The fifth proposal being submitted to stockholders for action is the approval of the compensation of Dr. Ji as Executive Chairperson of Scilex Holding Company. The Company did not receive any other stockholder proposals for this year's annual meeting. Because no further business is scheduled to come before the stockholders, we will move on to voting. I now direct that a vote of the stockholders be taken on the foregoing matters. Each holder of common stock is entitled to one vote for each share of common stock held of record at the close of business on September 24, 2021. Any stockholder who has previously given his, her, or its proxy need not vote unless he, she, or it decides to revoke the proxy and vote by electronic ballot at this meeting. No ballots or proxy revocations or changes of proxy will be accepted after the polls are closed. We're giving a little bit more time for marking the ballots and the electronic voting. We will allow for two more minutes for marking the ballots and electronic vote. All participants are now muted. Press star six to unmute your line. Your line is muted. One more minute for voting. I declare the polls for each matter voted upon this meeting closed at 12:15 P.M. Pacific today, and the Inspector of Election to tabulate the ballots. Will the Secretary please report the preliminary results of the voting? Yes. Although all the numbers on the share vote are not in, I can provide the following preliminary results from the Inspector of Election. Starting with the first proposal, Dr. Ji, Mr. Followwill, Dr. Janda, Mr. Lemus, Mr. Shah, Dr. Wu, and Ms. Czerepak have been elected as directors and will each serve for the term expiring on the date of the Company's 2022 annual meeting. For the second proposal, ratification of the appointment of Ernst & Young to act as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021, has been approved. Turning to the third proposal, the advisory approval of the compensation of our named executive officers has passed. For the fourth proposal, I have been advised that more of the votes cast voted for holding an annual advisory vote on the compensation of the Company's named executive officers than any other option. Finally, a majority of the votes cast were not in favor of approving the compensation of Dr. Ji as Executive Chairperson of Scilex Holding Company. The Inspector of Election has indicated that you will furnish me with a written report of the final vote count with respect to the matters voted on today. A final tally of the votes will be published in a current report on Form 8-K filed with the SEC on or before November 19, 2021. Thank you, Brian. Please include the Inspector of Election's written report of the final vote count in the minutes for today's meeting. That being no further business to come before the meeting, the 2021 annual meeting of stockholders of Sorrento Therapeutics is now adjourned. Now, we would like to answer some stockholders' questions that we received today in the web portal. Please note, we will attempt to answer as many questions as time allows, but only questions that are relevant to the meeting will be addressed. For questions about our IND pipeline and clinical programs, please visit Sorrento's website to view our corporate presentation additional information. Will the Secretary please advise if we have any questions? Thank you, Henry. At this time, we have no questions for purposes that relate to this meeting. As you noted, questions about our R&D pipeline and clinical programs will be made available on our website and in our corporate presentation. This concludes our Q&A session. Thank you all for attending today's meeting and for your continued support of Sorrento Therapeutics. Have a great day. Thank you. This now concludes the meeting. Thank you for joining, and have a pleasant day.